Massachusetts General Hospital and Brigham and Women’s Hospital are studying whether the antiviral tecovirimat helps treat monkeypox infections, and people in the Boston-area who have monkeypox can “make a huge contribution” to this study, according to Mass General Brigham.
The Boston hospital sites are part of a national trial that will enroll more than 500 adults with monkeypox virus infections after the global outbreak emerged months ago.
The trial called STOMP — Study of Tecovirimat for Human Monkeypox Virus — will gather data from a broad population of people with monkeypox to determine if participants receiving tecovirimat heal more quickly and have less pain compared with those taking placebo.
“We need studies like STOMP to know if a drug is working effectively and if it’s going to be the best treatment for our patients,” said MGH site principal investigator Elizabeth Hohmann.
“Randomized, double-blind clinical trials give us vital information to improve clinical care, and people living in the Boston area who have monkeypox have the opportunity to make a huge contribution by participating in this study,” added Hohmann, of the Infectious Diseases Division at MGH.
Since the spring, more than 56,000 monkeypox cases have been reported across the world and more than 21,000 cases confirmed in the U.S. — including more than 400 cases reported in Massachusetts.
Stay connected with us on social media platform for instant update click here to join our Twitter, & Facebook
We are now on Telegram. Click here to join our channel (@TechiUpdate) and stay updated with the latest Technology headlines.
For all the latest Health & Fitness News Click Here
